Cited 10 times in
Patient Experience of Symptoms and Side Effects when Treated with Osimertinib for Advanced Non-Small-Cell Lung Cancer: A Qualitative Interview Substudy
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 김혜련 | - |
dc.date.accessioned | 2020-07-16T16:52:15Z | - |
dc.date.available | 2020-07-16T16:52:15Z | - |
dc.date.issued | 2017-10 | - |
dc.identifier.issn | 1178-1653 | - |
dc.identifier.uri | https://ir.ymlib.yonsei.ac.kr/handle/22282913/178358 | - |
dc.description.abstract | Introduction: Capturing the patient experience during treatment is important to both regulatory authorities and to patients starting treatment. We identified the symptoms and side effects experienced by patients with advanced non-small-cell lung cancer during osimertinib treatment, to understand treatment expectations, satisfaction, and the level of difficulty coping with the side effects experienced during treatment. Methods: Qualitative interviews (approximately 4-6 weeks after treatment initiation and again after approximately 4 months of treatment) were conducted during the phase I/II AURA clinical trial of osimertinib, a tyrosine kinase inhibitor of epidermal growth factor receptor-sensitizing and T790M resistance mutations. Results: During the first interview (23 patients), the most commonly reported symptoms/side effects were coughing, itching, tiredness (each reported by 56.5% of patients), and rash (43.5%). During the second interview (21 patients), compared with the first interview, shortness of breath and diarrhea were reported by more patients (57.1 and 38.1%, respectively; both increased from 34.8%); tiredness remained predominant (42.9%); and itching (38.1%), coughing (38.1%), and rash (14.3%) were reported by fewer patients. At both interviews, the most frequently reported symptoms/side effects were also those most often rated by patients for bothersomeness and severity, and generally received mean scores in the low-to-moderate range. However, several rarely expressed symptoms/side effects (e.g., abdominal pain, frequent day time urination) received high bothersomeness ratings. At the second interview, patients were highly satisfied with osimertinib and had a low level of difficulty in coping with side effects during treatment. Conclusions: These data enhance our understanding of patients' experiences of symptoms/side effects, which could increase the accuracy of the osimertinib benefit-risk assessment, guide management of adverse events, and improve the information given to patients receiving the drug. | - |
dc.description.statementOfResponsibility | restriction | - |
dc.language | English | - |
dc.publisher | Adis, Springer International | - |
dc.relation.isPartOf | PATIENT-PATIENT CENTERED OUTCOMES RESEARCH | - |
dc.rights | CC BY-NC-ND 2.0 KR | - |
dc.title | Patient Experience of Symptoms and Side Effects when Treated with Osimertinib for Advanced Non-Small-Cell Lung Cancer: A Qualitative Interview Substudy | - |
dc.type | Article | - |
dc.contributor.college | College of Medicine (의과대학) | - |
dc.contributor.department | Dept. of Internal Medicine (내과학교실) | - |
dc.contributor.googleauthor | Anna Rydén | - |
dc.contributor.googleauthor | Fiona Blackhall | - |
dc.contributor.googleauthor | Hye Ryun Kim | - |
dc.contributor.googleauthor | Rathi N Pillai | - |
dc.contributor.googleauthor | Lauren Braam | - |
dc.contributor.googleauthor | Mona L Martin | - |
dc.contributor.googleauthor | Andrew Walding | - |
dc.identifier.doi | 10.1007/s40271-017-0229-9 | - |
dc.contributor.localId | A01166 | - |
dc.relation.journalcode | J03844 | - |
dc.identifier.eissn | 1178-1661 | - |
dc.identifier.pmid | 28353220 | - |
dc.identifier.url | https://link.springer.com/article/10.1007/s40271-017-0229-9 | - |
dc.subject.keyword | Bothersome Symptom | - |
dc.subject.keyword | Epidermal Growth Factor Receptor | - |
dc.subject.keyword | Initial Interview | - |
dc.subject.keyword | Poor Appetite | - |
dc.subject.keyword | Transcript Database | - |
dc.contributor.alternativeName | Kim, Hye Ryun | - |
dc.contributor.affiliatedAuthor | 김혜련 | - |
dc.citation.volume | 10 | - |
dc.citation.number | 5 | - |
dc.citation.startPage | 593 | - |
dc.citation.endPage | 603 | - |
dc.identifier.bibliographicCitation | PATIENT-PATIENT CENTERED OUTCOMES RESEARCH, Vol.10(5) : 593-603, 2017-10 | - |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.